51 , while it has little impact on the growth of commensal probiotics (such as Lactobacillus and Bifidobacterium ), which provides valuable evidence for the potential activity of this herb against gut microbiota during AILD treatment ( Bifidobacterium and Lactobacillus ) while reducing the abundance of some intestinal opportunistic pathogenic microbiota (such as Proteus , Veillonella , Prevotella , Neisseria and Actinomyces ) ( Bifidobacterium and Lactobacillus were found to be significantly reduced in multiple types of AILD, while opportunistic pathogens were significantly elevated
Macroalbuminuria occurred less (2.2%) in exenatide group compared to placebo group (2.5%) [HR 0.87 (95% CI: 0.701.07)]
On the other hand, administration of tirzepatide at a dose of 70 nmol/kg/day, resulted in a significant weight loss associated with shorter femur compared to saline-treated diabetic mice, but no evident alterations of bone microarchitecture or strength [69]
This effect is dose-dependent, with appetite suppression often increasing during dose titration (usually starting at 0.25mg weekly, then increasing to 0.5mg or 1mg)